Oncofetal protein IMP3, a new diagnostic biomarker to distinguish malignant mesothelioma from reactive mesothelial proliferation.

@article{Shi2011OncofetalPI,
  title={Oncofetal protein IMP3, a new diagnostic biomarker to distinguish malignant mesothelioma from reactive mesothelial proliferation.},
  author={Min Shi and A. T. Espinoza Fraire and Peiguo G. Chu and Kristine M Cornejo and Bruce A. Woda and Karen Dresser and Kenneth L. Rock and Zhong Jiang},
  journal={The American journal of surgical pathology},
  year={2011},
  volume={35 6},
  pages={
          878-82
        }
}
The distinction of malignant mesothelioma from reactive mesothelial proliferation remains to be a major challenge for surgical pathologists. In this study, we investigated whether insulin-like growth factor II messenger ribonucleic acid-binding protein 3 (IMP3), an oncofetal protein, can be used as a biomarker to distinguish between malignant and reactive mesothelial cells. A total of 109 cases (mesothelioma, n=45; reactive mesothelial proliferation, n=64) were examined by immunohistochemistry… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 30 CITATIONS

Pathological and molecular biological approaches to early mesothelioma

  • International Journal of Clinical Oncology
  • 2011
VIEW 12 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED